Background: Immunotherapy has become an efcacious option in the management of solid organ malignancies. Immune-related adverse events including pneumonitis are well described and may be particularly of concern in patients receiving immunotherapy for non-small-cell lung cancer. Case presentations: In this paper, we describe three cases of immunotherapy-induced pneumonitis occurring in the management of lung malignancy. Our cases include a 54-year-old Caucasian woman with squamous cell lung cancer who was successfully rechallenged with immunotherapy after prior significant pneumonitis, a 65-year-old Caucasian man with metastatic squamous cell lung cancer who developed pneumonitis after multiple cycles of uneventful immunotherapy, and a 73-yea...
The use of antibodies against programmed cell death 1 (PD-1), which block inhibitory T-cell checkpoi...
In patients with primary or secondary lung tumour treated with immune checkpoint inhibitors, immune-...
Background: Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have quickly become s...
BACKGROUND: Immunotherapy has become an efficacious option in the management of solid organ malignan...
Abstract Background Immunotherapy has become an efficacious option in the management of solid organ ...
Background: Immunotherapy has become an efficacious option in the management of solid organ malignan...
Immunotherapy is the most promising method in the treatment of lung cancer, especially in connection...
Abstract Background In recent years, the application of immunotherapy combined with chemotherapy in ...
Introduction: Lung cancer is one of the most common cancers in the world and it is the leading cause...
Radiation recall pneumonitis (RRP) is a rare inflammatory reaction that occurs in previously irradia...
Abstract Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an...
Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti-programmed death-1 (PD-1...
Background Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related...
International audienceImmune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatmen...
Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis betwee...
The use of antibodies against programmed cell death 1 (PD-1), which block inhibitory T-cell checkpoi...
In patients with primary or secondary lung tumour treated with immune checkpoint inhibitors, immune-...
Background: Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have quickly become s...
BACKGROUND: Immunotherapy has become an efficacious option in the management of solid organ malignan...
Abstract Background Immunotherapy has become an efficacious option in the management of solid organ ...
Background: Immunotherapy has become an efficacious option in the management of solid organ malignan...
Immunotherapy is the most promising method in the treatment of lung cancer, especially in connection...
Abstract Background In recent years, the application of immunotherapy combined with chemotherapy in ...
Introduction: Lung cancer is one of the most common cancers in the world and it is the leading cause...
Radiation recall pneumonitis (RRP) is a rare inflammatory reaction that occurs in previously irradia...
Abstract Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an...
Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti-programmed death-1 (PD-1...
Background Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related...
International audienceImmune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatmen...
Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis betwee...
The use of antibodies against programmed cell death 1 (PD-1), which block inhibitory T-cell checkpoi...
In patients with primary or secondary lung tumour treated with immune checkpoint inhibitors, immune-...
Background: Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have quickly become s...